BRIEF published on 04/17/2026 at 21:05, 6 months 23 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 6 months 23 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
PRESS RELEASE published on 04/17/2026 at 21:00, 6 months 23 days ago Inside Information / Other news releases Innate Pharma to present interim results of IPH5201 in MATISSE Phase 2 study at AACR 2026. Study aims to enhance NSCLC treatment with anti-CD39 monoclonal antibody NSCLC Innate Pharma AACR 2026 MATISSE Phase 2 IPH5201
PRESS RELEASE published on 04/17/2026 at 21:00, 6 months 23 days ago Informations privilégiées / Autres communiqués Innate Pharma présentera des résultats intermédiaires de l'essai de Phase 2 MATISSE évaluant IPH5201 lors d'une session plénière dédiée aux essais cliniques au congrès de l'AACR 2026 Essai Clinique Cancer Du Poumon Innate Pharma AACR 2026 IPH5201
BRIEF published on 04/13/2026 at 07:05, 6 months 27 days ago Innate Pharma met à jour ses actions et ses droits de vote à compter d'avril 2026 Biotechnologie Innate Pharma Actions Et Droits De Vote Avril 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 6 months 27 days ago Innate Pharma : Mise à Jour du Capital et des Droits de Vote Droits De Vote Biotechnologie Actions Immunothérapie Innate Pharma
BRIEF published on 04/13/2026 at 07:05, 6 months 27 days ago Innate Pharma Updates Share and Voting Rights as of April 2026 Biotechnology Shares And Voting Rights Innate Pharma April 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 6 months 27 days ago Innate Pharma: Capital and Voting Rights Update Voting Rights Biotechnology Actions Immunotherapy Innate Pharma
PRESS RELEASE published on 04/13/2026 at 07:00, 6 months 27 days ago Inside Information / Other news releases Innate Pharma releases total shares and voting rights as of April 9, 2026, in compliance with French regulations. Learn about its innovative immunotherapies for cancer patients Voting Rights Shares French Regulations Innate Pharma Immunothérapies
PRESS RELEASE published on 04/13/2026 at 07:00, 6 months 27 days ago Inside Information / Other news releases Innate Pharma to hold its Annual General Meeting of shareholders on May 21, 2026 at 10:30 a.m. CEST in Marseille. Shareholders must register shares by May 14, 2026, 00:00 Paris time, to attend Annual General Meeting Shareholders Registration Innate Pharma Marseille
Published on 11/10/2026 at 21:00, 29 minutes ago Golden Minerals Announces Completion of Offering for C$5,000,000
Published on 11/10/2026 at 14:45, 6 hours 44 minutes ago An Investigational Drug to Tackle Measles Outbreaks
Published on 11/10/2026 at 14:31, 6 hours 58 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 6 hours 59 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:30, 6 hours 59 minutes ago ACCESS Newswire Reports Third Quarter 2026 Results
Published on 11/10/2026 at 19:21, 2 hours 8 minutes ago ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Published on 11/10/2026 at 18:54, 2 hours 34 minutes ago REPLOID Group AG pursues entry in the US market and secures exclusivity to conduct due diligence for the potential acquisition of Chapul, LLC.
Published on 11/10/2026 at 18:45, 2 hours 44 minutes ago Special Optics Introduces Purpose-Built Microscope Objectives for Quantum Applications
Published on 11/10/2026 at 18:30, 2 hours 59 minutes ago Shelly Group Accelerates Revenue Growth in the Third Quarter and Confirms Full-Year 2026 Guidance
Published on 11/10/2026 at 18:00, 3 hours 29 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 3 hours 44 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 3 hours 54 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 3 hours 58 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
